Provider review
Kin Meds review
The figure it leads with is labeled a consultation in its own comparison table.
The compounded line is priced cleanly per molecule. The branded route has no medication price anywhere on the site.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Kin Meds
$199/mo sema · $249/mo tirz compounded
FDA warning letter · Kin Meds · February 2026 · addressed to Kin Meds. Details in our review.
- Vs median
- $30/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
There are two businesses on this site and they are priced very differently. The compounded line is straightforward: one figure per molecule, both readable before intake, described as personalized formulations that may carry additives such as B12 at the prescriber's discretion. Those are the numbers worth quoting, because they are the ones that buy medication. The branded line is where a reader should slow down. The site leads with a figure well below either compounded price and attaches it to a branded product, and the only place that figure is defined is the company's own side-by-side comparison table, where the starting price for both the pen and the pill is given as a consultation. A consultation fee and a medication price are different things by an order of magnitude for branded GLP-1s, and nothing on the site publishes what the drug itself would cost, so a reader arriving on the headline number has no way to reach a total. That is worth stating plainly rather than assuming the worst: the compounded products are honestly priced and reasonable, and the number the marketing pushes hardest is the one that buys the least. No milligram is attached to anything here, so the usual question cannot be answered from any of these figures.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the compounded route, where one clear figure per molecule is published
- You want personalized formulations described honestly, additives and all
- You want branded and compounded offered by the same clinicians so you can switch
Look elsewhere if
- You arrived on the headline figure. That one is labeled a consultation, not medication
- You want the branded route costed. No medication price for it appears on the site
- You want a figure tied to a milligram. None of them is
What it actually costs
Price as published
Compounded personalized semaglutide from $199/mo and compounded personalized tirzepatide from $249/mo, both described as formulations that may include patient-specific additives such as B12 · the figure the site leads with is smaller and is not a medication price: the homepage advertises "starting at $149/month" and prints "Wegovy Injection starting at $149/mo" with a footnote marker, and the company's own Wegovy comparison table gives the starting price for both the pen and the pill as "$149/mo Consultation" · on that reading the branded medication is billed separately and its cost is published nowhere on the site · branded Wegovy, Zepbound and Foundayo are offered and none of them carries a medication figure · no dose sits behind any number here · the disclaimer states the company is not affiliated with or endorsed by either manufacturer
- Vs median
- $30/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. The compounded line is straightforward — one figure per molecule, both readable before intake, described as personalized formulations that may carry additives at the prescriber's discretion. The figure the site LEADS with is smaller than either and is labeled "Consultation" in the company's own comparison table, against branded products whose medication cost is published nowhere. So the number the marketing pushes hardest is the one that buys the least, and the branded route cannot be totaled from anything public. No dose sits behind any figure and no low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- The compounded line carries one clear figure per molecule, readable before intake.
- Formulations are described honestly as personalized, with additives at the prescriber's discretion.
- Branded and compounded options sit on the same site, so the two routes can be weighed.
Pharmacy, labs and oversight
Kin Meds does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Kin Meds publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- FDA warning letter on fileOne is on file. The disclosure and the FDA's own database are directly below.
- On file
FDA warning letter
The U.S. Food and Drug Administration issued a warning letter to Kin Meds in February 2026. It is addressed to Kin Meds — search that name, not ours, to find it. We are not summarizing what it says — read it at the source. This does not change how Kin Meds is listed here or whether we are paid for a click to it, and we would rather you knew both of those things at once.
How the program works
There are two businesses on this site and they are priced very differently. The compounded line is straightforward: one figure per molecule, both readable before intake, described as personalized formulations that may carry additives such as B12 at the prescriber's discretion. Those are the numbers quoted here because they are the ones that buy medication. The branded line is where a reader should slow down. The site leads with a figure well below either compounded price and attaches it to a branded product, and the only place that figure is defined is the company's own side-by-side comparison table, where the starting price for both the pen and the pill is given as a consultation. A consultation fee and a medication price are different things by an order of magnitude for branded GLP-1s, and nothing on the site publishes what the drug itself would cost, so a reader arriving on the headline number has no way to reach a total. That is worth stating plainly rather than assuming the worst: the compounded products are honestly priced and reasonable, and the number the marketing pushes hardest is the one that buys the least. No milligram is attached to anything here, so the usual question — what does a deliberately small dose cost — cannot be answered from any of these figures.
The honest cons
The headline figure is labeled a consultation in the company's own comparison table.
- No branded medication is priced, so that route cannot be totaled from the site.
- No dose sits behind any figure, compounded or branded.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Kin Meds is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#238 of 373
Ordered with the companies that pay us first, and Kin Meds is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.